Late-phase trial failure for GSK, Prosensa muscular dystrophy drug

09/23/2013 | PharmaTimes (U.K.)

A Phase III trial for drisapersen, a drug by GlaxoSmithKline and Prosensa for treating Duchenne muscular dystrophy, failed to meet primary goals three months after receiving breakthrough therapy designation from the U.S. FDA. The trial among 186 boys suffering from the disease failed to demonstrate significant improvement in walking distance or motor function, compared with a placebo. DMD affects one in 3,500 live male births.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Idaho Regional Director
Boise, ID
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA